Drug intelligence / Profile preview

TBD201

Development stage: Preclinical
Lead developer: FibroGenesis
Modality: Cell Therapies

Overview

TBD201 is an allogeneic cell therapy candidate developed by FibroGenesis for the treatment of diabetes. The therapy utilizes human dermal fibroblasts (HDFs) to facilitate the engraftment and survival of pancreatic islets. By leveraging the regenerative and supportive properties of fibroblasts, TBD201 aims to enhance the efficacy of islet transplantation, a procedure often limited by poor cell survival and integration. The program is currently in preclinical development.

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on TBD201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBD201.

Explore the full profile